Activity of CuDIPS against mammary cancer in C3H HeNCR mice.

A copper complex with superoxide dismutase mimetic activity, Cu(II)2 (3,5-diisopropylsalicylate)4 (CuDIPS), was tested for activity against mammary cancer in female C3H/HeNCR mice. Initiation of treatment at 20 or at 30 weeks of age had a limited beneficial effect on survival rates. Further, a small, but not statistically significant, difference in tumorigenesis was observed in comparisons between experimental and control groups of animals. Implications of these findings are discussed.